Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy: The VANISH Trial. 2018

Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
Health Economics Research Group, Institute of Environment, Health and Societies, Brunel University, London, United Kingdom.

This analysis uses the data from the randomized controlled trial to assess the cost effectiveness of catheter ablation (n = 132) versus escalated antiarrhythmic therapy (n = 127). For survivors of myocardial infarction with implantable cardioverter-defibrillator shocks despite antiarrhythmic drugs, the VANISH (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease) trial demonstrated improved clinical outcomes with catheter ablation compared with more aggressive antiarrhythmic pharmacotherapy. Health care resource use and quality-of-life data were used to determine the cost effectiveness of catheter ablation. Published references were used to estimate costs (in 2015 Canadian dollars). The analysis was over 3 years, with a 5% discount rate. Adjustment was made for censoring and baseline utilities. Ablation resulted in greater quality-adjusted life-years (QALYs) than escalated drug therapy did (1.63 vs. 1.49; difference: 0.14; 95% confidence interval [CI]: -0.20 to 0.46) and higher cost ($65,126 vs. $60,269; difference: $4,857; 95% CI: -$19,757 to $27,106); with an incremental cost per QALY gained for ablation versus escalated drug therapy of $34,057 primarily due to the initial costs of ablation, which were partially offset by the costs of subsequent ablations and adverse outcomes in the escalated drug therapy arm. For patients with amiodarone-refractory ventricular tachycardia, ablation dominated escalated drug therapy, with greater QALYs (1.48 vs. 1.26; difference: 0.22; 95% CI: -0.19 to 0.59) and lower costs ($67,614 vs. $68,383; difference: -$769; 95% CI: -$35,330 to $27,092). For those with sotalol-refractory ventricular tachycardia, ablation resulted in similar QALYs (1.90 vs. 1.90; difference: -0.00; 95% CI: -0.59 to 0.62) and higher costs ($60,455 vs. $45,033; difference: $15,422; 95% CI: -$10,968 to $48,555). For the total trial population, results are suggestive that ablation is cost effective compared with escalation of drug therapy. This result was only manifest for the subgroup of patients whose qualifying arrhythmia occurred despite amiodarone.

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D015233 Models, Statistical Statistical formulations or analyses which, when applied to data and found to fit the data, are then used to verify the assumptions and parameters used in the analysis. Examples of statistical models are the linear model, binomial model, polynomial model, two-parameter model, etc. Probabilistic Models,Statistical Models,Two-Parameter Models,Model, Statistical,Models, Binomial,Models, Polynomial,Statistical Model,Binomial Model,Binomial Models,Model, Binomial,Model, Polynomial,Model, Probabilistic,Model, Two-Parameter,Models, Probabilistic,Models, Two-Parameter,Polynomial Model,Polynomial Models,Probabilistic Model,Two Parameter Models,Two-Parameter Model
D017115 Catheter Ablation Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias. Ablation, Transvenous Electric,Catheter Ablation, Electric,Catheter Ablation, Percutaneous,Catheter Ablation, Radiofrequency,Catheter Ablation, Transvenous,Ablation, Catheter,Ablation, Transvenous Electrical,Catheter Ablation, Electrical,Electric Catheter Ablation,Electrical Catheter Ablation,Percutaneous Catheter Ablation,Radiofrequency Catheter Ablation,Transvenous Catheter Ablation,Ablation, Electric Catheter,Ablation, Electrical Catheter,Ablation, Percutaneous Catheter,Ablation, Radiofrequency Catheter,Ablation, Transvenous Catheter,Electric Ablation, Transvenous,Electrical Ablation, Transvenous,Transvenous Electric Ablation,Transvenous Electrical Ablation
D017180 Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). Idiopathic Ventricular Tachycardia,Nonsustained Ventricular Tachycardia,Paroxysmal Supraventricular Tachycardia,Ventricular Tachyarrhythmias,Ventricular Tachycardia,Idiopathic Ventricular Tachycardias,Nonsustained Ventricular Tachycardias,Paroxysmal Supraventricular Tachycardias,Supraventricular Tachycardia, Paroxysmal,Tachyarrhythmia, Ventricular,Tachycardia, Idiopathic Ventricular,Tachycardia, Nonsustained Ventricular,Tachycardia, Paroxysmal Supraventricular,Ventricular Tachyarrhythmia,Ventricular Tachycardia, Idiopathic,Ventricular Tachycardia, Nonsustained,Ventricular Tachycardias
D019057 Quality-Adjusted Life Years A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994) Adjusted Life Year,Healthy Years Equivalent,QALYs,QUALYs,Quality Adjusted Life Year,Quality-Adjusted Life Year,Adjusted Life Years,Healthy Years Equivalents,Quality Adjusted Life Years,Equivalents, Healthy Years,Life Year, Adjusted,Life Year, Quality-Adjusted,Life Years, Adjusted,Life Years, Quality-Adjusted,QUALY,Years, Adjusted Life

Related Publications

Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
October 2016, The New England journal of medicine,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
October 2016, The New England journal of medicine,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
July 2016, The New England journal of medicine,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
January 2018, Circulation. Arrhythmia and electrophysiology,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
July 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
July 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
June 2023, JACC. Clinical electrophysiology,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
August 2022, Circulation,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
April 2022, Journal of the American College of Cardiology,
Kathryn Coyle, and Doug Coyle, and Isabelle Nault, and Ratika Parkash, and Jeffrey S Healey, and Christopher J Gray, and Martin J Gardner, and Laurence D Sterns, and Vidal Essebag, and Tomasz Hruczkowski, and Louis Blier, and George A Wells, and Anthony S L Tang, and William G Stevenson, and John L Sapp
July 2023, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Copied contents to your clipboard!